Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05001451
Other study ID # GDX012U-001
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date August 13, 2021
Est. completion date June 3, 2022

Study information

Verified date July 2022
Source GammaDelta Therapeutics Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this first-in-human study is to assess the safety, tolerability, antileukemic activity and maximum tolerated dose (MTD) of GDX012 in AML patients who are MRD positive by multiparametric flow cytometry. The study will consist of a dose escalation stage to evaluate various doses of GDX012 after a lymphodepletion regimen comprising fludarabine and cyclophosphamide. Following determination of the MTD of GDX012, the study will expand at the MTD. Patients will be followed up for 12 months, after receiving GDX012.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date June 3, 2022
Est. primary completion date June 3, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - = 18 years old - Weight = 40 kg - Anticipated life expectancy > 3 months prior to lymphodepletion - Karnofsky Performance Score = 70% - Histologically confirmed diagnosis of AML - In complete response (CR) (including CRi/CRp); patients in first, second or subsequent CR (including CRi/CRp) are permitted - MRD detected in bone marrow by MFC - Negative pregnancy test (females of childbearing potential only) - Agree to use effective birth control - Left ventricular ejection fraction (LVEF) = 50% - Platelet Count = 20 x 109/L - Prothrombin Time or INR = 1.5 x ULN (unless receiving therapeutic anticoagulation) - Partial Thromboplastin Time = 1.5 x ULN (unless receiving therapeutic anticoagulation) - Hemoglobin = 8.0 g/dL - Creatinine Clearance = 40mL/min - Serum Total Bilirubin = 1.5 x ULN (unless documented Gilbert's Syndrome with Direct Bilirubin < 35% of Total Bilirubin) - ALT = 2.5 x ULN Exclusion Criteria: - Cytotoxic chemotherapy within 3 weeks - Immune therapy within 4 weeks - Immunosuppressive therapy within 2 weeks (with exceptions) - Investigational treatment or interventional clinical trial within 4 weeks or 5 half-lives (if known), whichever is longer - Major surgery within 4 weeks and/or not fully recovered from surgery-related toxicities - Known hypersensitivity to chemotherapy, other agents, or excipients used in this study - Female patient that is pregnant or lactating/breastfeeding - Ongoing toxicity from prior anti-cancer therapy that have not recovered to = Grade 1 (with exceptions) - History of chronic or recurrent autoimmune or immune-mediated disease requiring steroids or other immunosuppressive treatments (including anti-tumor necrosis factor agents) - Active CNS involvement (i.e. leukemic infiltration) - Any other malignancy that requires active therapy - Uncontrolled intercurrent illness (i.e. acute coronary syndrome in the last 6 months) - Active infection with HIV, Hepatitis B or Hepatitis C NOTE: other protocol defined inclusion/exclusion criteria may apply.

Study Design


Intervention

Biological:
GDX012 Suspension for IV Infusion
Biological: GDX012 Suspension for IV Infusion (single dose) following chemotherapy for lymphodepletion. Drug: Fludarabine; chemotherapy for lymphodepletion Drug: Cyclophosphamide; chemotherapy for lymphodepletion

Locations

Country Name City State
United States City of Hope Duarte California

Sponsors (1)

Lead Sponsor Collaborator
GammaDelta Therapeutics Limited

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of treatment emergent adverse events (AEs) and serious adverse events (SAEs) AEs and SAEs occurring following administration of GDX012 Up to 100 days
Primary Incidence of treatment emergent clinically significant abnormal laboratory assessments Standard clinical laboratory assessments for organ function (i.e. heart, kidney, liver) Up to 100 days
Primary Incidence of dose limiting toxicities (DLTs) DLTs occurring following administration of GDX012, measured using CTCAE 5.0 criteria Up to 100 days
Primary Establish the maximum tolerated dose (MTD) of GDX012 Up to 100 days
Secondary Evaluate the antileukemic activity of GDX012 Minimal residual disease (MRD) assessed by flow cytometry Up to 1 year
Secondary Evaluate the antileukemic activity of GDX012 Incidence of patients converting from MRD positive to MRD negative Up to 1 year
Secondary Evaluate the antileukemic activity of GDX012 Progression-free survival (PFS) and overall survival (OS) Up to 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2